Adamed Pharma S.A. — Sponsor Intelligence | 14 EU Trials

Filter these 14 trials by condition, phase, country and more.

Open in Search →

14 Registered trials

2 Recruiting

11 Completed trials

4 Countries active

7 Unique IMPs

100% Results reported

Phase I (Other)

Other

Phase III: 1 Phase I: 1 Phase I (Other): 5 Other: 7

100%

11 of 11 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Chronic kidney disease 2 Type 2 diabetes mellitus 2 Cardiac failure 2 Schizophrenia 2 Hypertension 2 Avian influenza 1 Benign prostatic hyperplasia 1 Bacterial vaginosis 1

Top IMPs

RAMIPRIL 2 AMLODIPINE 1 CLINDAMYCIN PHOSPHATE 1 FURAZIDINE 1 INDAPAMIDE 1 RAMIPRIL, AMLODIPINE BESILATE, ROSUVASTATIN CALCIUM 1 ROSUVASTATIN CALCIUM 1

All trials

14 total

Randomized, open-label, multiple dose, two-period, two-treatment, cross-over pharmacodynamic study in healthy male and female participants u… Pending

2026-526556-31-00 Phase I (Other) 1 country
A Phase III, randomized, controlled study of furazidin for bacterial vaginosis. Recruiting

2024-515332-80-00 Phase III 4 countries CLINDAMYCIN PHOSPHATE; FURAZIDINE
Clinical study to evaluate the safety of investigational medicinal product called AD-O51.4 in patients with advanced malignancies Recruiting

2024-515687-31-01 Phase I 1 country
The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatm… Ended

2025-523325-18-00 1 country
The pivotal bioequivalence study comparing the test product to the reference product, which belong to the group of medicines used in the tre… Ended

2025-522975-27-00 1 country
The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatm… Ended

2025-522976-10-00 1 country
The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatm… Ended

2025-521400-21-00 1 country
The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatm… Ended

2024-515436-76-00 1 country
Randomized, open-label, single dose, two-period, two-treatment, cross-over bioequivalence study comparing test product Rivaroxaban/Acetylsal… Ended

2024-513665-40-00 1 country
A randomized, open-label, single dose, cross-over study to evaluate the drug-drug interaction between Proscar 5 mg, film-coated tablets and … Ended

2024-510774-24-00 Phase I (Other) 1 country
Randomized, open-label, single dose, three-period, three treatment cross-over bioavailability study comparing test products Rosuvastatin/Eze… Ended

2023-507048-35-00 Phase I (Other) 1 country
A randomized, open-label, single dose, cross-over bioavailability study evaluating the drug-drug interaction between Tritace 10, 10 mg, tabl… Ended

2023-505887-12-00 Phase I (Other) 1 country INDAPAMIDE; RAMIPRIL
Randomized, open-label, single dose, four-period, cross-over drug-drug interaction study comparing reference products Crestor 20 mg film coa… Ended

2023-505153-41-00 Phase I (Other) 1 country
Randomized, open-label, single dose, two-period, cross-over bioequivalence study comparing test formulation Rosuvastatin/Amlodipine/Ramipril… Ended

2023-503822-38-00 1 country AMLODIPINE; RAMIPRIL; RAMIPRIL, AMLODIPINE BESILATE, ROSUVASTATIN CALCIUM; ROSUV…

Showing 1–14 of 14 trials

← All sponsors A–Z